Multiple myeloma (MM) is a neoplastic plasma cells (PC) disease that has a heterogeneous
clinical course and outcome. MM is usually associated, particularly in the advanced forms, with lytic
bone lesions, anemia, renal impairment and increased bone marrow angiogenesis. Several factors like
activating factors of osteoclast, pro-angiogenic factors, cytokines, growth factors, adhesion molecules
and proteinases are involved in these manifestations. Although several aspects of the MM pathogenesis
remain uncertain, significant progress occurred in the last decade. This chapter focuses on the current
knowledge of the molecular pathogenesis of the disease as well as the pathogenesis of angiogenesis,
bone involvement, anemia and renal impairment, which are frequent in MM patients.
Keywords: Stages of MM, Hyperdiploid (HD), non-hyperdiploid (NHD), VDJ Recombination,
Immunoglobulin Heavy Chain (IgH), Plasma-Cell Leukemia (PCL), Angiogenesis, Bone Disease, Bone
Marrow Stromal Cells (BMSC), Osteoprotegerin, RANKL Inhibitor, Anemia in Multiple Myeloma ,
Renal Failure, Physiopathogenesis of renal disease in multiple myeloma.
